Advanced Malignancies Clinical Trials

8 recruiting

Advanced Malignancies Trials at a Glance

9 actively recruiting trials for advanced malignancies are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Madrid, New York, and Barcelona. Lead sponsors running advanced malignancies studies include BioRay Pharmaceutical Co., Ltd., BioInvent International AB, and Beijing Mabworks Biotech Co., Ltd..

Browse advanced malignancies trials by phase

Treatments under study

About Advanced Malignancies Clinical Trials

Looking for clinical trials for Advanced Malignancies? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 1

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.164 enrolled1 locationNCT06038058
Recruiting
Phase 1

A Study of BR111 in Patients With Advanced Malignancies

Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.166 enrolled1 locationNCT06937957
Recruiting
Phase 3

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting
Phase 1

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Advanced Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology260 enrolled1 locationNCT06717880
Recruiting
Phase 1

A Clinical Study of MIL95 in Advanced Malignancies.

Advanced Malignancies
Beijing Mabworks Biotech Co., Ltd.58 enrolled1 locationNCT04651348
Recruiting
Phase 1

A Study of IBI363 in Subjects With Advanced Malignancies

Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.556 enrolled1 locationNCT06468098
Recruiting
Phase 1Phase 2

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Metastatic Breast CancerRecurrent Breast CancerAdvanced Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.154 enrolled2 locationsNCT06202261